SAB Biotherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	29.42	8.9	56.57	15.05	33.21	12.61
Short-Term Investments	81.46	11.86	-	-	-	-
Cash & Short-Term Investments	110.88	20.76	56.57	15.05	33.21	12.61
Cash Growth	264.73%	-63.30%	275.93%	-54.69%	163.33%	98.72%
Accounts Receivable	-	-	-	5.56	8.01	20.57
Other Receivables	0.56	0.05	-	-	-	-
Receivables	0.56	0.05	-	5.56	8.01	20.57
Prepaid Expenses	1.84	2.98	2.34	1.49	2.64	1.28
Restricted Cash	-	-	-	-	6.34	-
Total Current Assets	113.28	23.79	58.91	22.1	50.19	34.46
Property, Plant & Equipment	19.44	19.92	24.68	28.34	30.95	22.08
Long-Term Deferred Charges	-	0.26	-	-	-	-
Other Long-Term Assets	0.12	0.22	0.35	0.47	-	-
Total Assets	183.45	44.2	83.94	50.9	81.14	56.54
Accounts Payable	2.95	1.69	0.95	3.68	4.46	7.38
Accrued Expenses	6.85	5.47	6.69	9.83	11.91	1.28
Current Portion of Long-Term Debt	-	0.28	1.05	0.77	1.8	0.54
Current Portion of Leases	0.99	0.54	0.8	0.62	1.3	1.12
Current Unearned Revenue	-	-	1.32	-	0.1	0.1
Other Current Liabilities	-	-	-	0.09	6.89	0.64
Total Current Liabilities	10.79	7.98	10.81	14.99	26.46	11.06
Long-Term Debt	-	-	-	0.54	-	0.17
Long-Term Leases	5.2	3.86	4.05	3.99	5.42	6.3
Other Long-Term Liabilities	2.38	6.39	11.77	0.32	10.72	-
Total Liabilities	18.37	18.23	26.64	19.85	42.59	17.53
Common Stock	0	0	0	0	0	0
Additional Paid-In Capital	264.55	155.79	152.86	84.45	67.67	50.99
Retained Earnings	-94.03	-124.17	-90.06	-47.87	-29.13	-11.98
Treasury Stock	-5.52	-5.52	-5.52	-5.52	-	-
Comprehensive Income & Other	0.07	-0.14	0.03	-	-	-
Total Common Equity	165.07	25.97	57.3	31.06	38.55	39.01
Shareholders' Equity	165.07	25.97	57.3	31.06	38.55	39.01
Total Liabilities & Equity	183.45	44.2	83.94	50.9	81.14	56.54
Total Debt	6.19	4.67	5.91	5.93	8.52	8.13
Net Cash (Debt)	104.69	16.09	50.66	9.12	24.69	4.48
Net Cash Growth	304.53%	-68.23%	455.59%	-63.07%	450.61%	-
Net Cash Per Share	10.87	1.74	9.17	2.09	9.03	1.66
Filing Date Shares Outstanding	47.61	9.29	9.23	5.04	4.3	3.52
Total Common Shares Outstanding	47.49	9.29	9.23	5.04	4.35	3.52
Working Capital	102.48	15.81	48.09	7.1	23.74	23.39
Book Value Per Share	3.48	2.80	6.21	6.16	8.86	11.08
Tangible Book Value	165.07	25.97	57.3	31.06	38.55	39.01
Tangible Book Value Per Share	3.48	2.80	6.21	6.16	8.86	11.08
Machinery	14.51	14.52	11.99	11.57	8.87	6.33
Construction In Progress	-	-	-	0.31	4.61	6.73
Leasehold Improvements	15.42	15.42	17.65	9.3	5.7	0.19

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q